Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy

Abstract

Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.

1 . A composition for enhancing an immune response against an antigen in a subject in need thereof, comprising:
 a) PD1 antibody or PDL1 antibody, or combination thereof, and   b) a synthetic antigen capable of generating an immune response in the subject, or an immunogenic fragment or variant thereof.   
     
     
         2 . The composition of  claim 1  wherein the synthetic antigen is an isolated DNA that encodes for the antigen. 
     
     
         3 . The composition of  claim 2  wherein the synthetic antigen is selected from the group consisting of: hTERT, prostate, WT1, tyrosinase, NYES01, PRAME, MAGE, CMV, herpes, HIV, HPV, HCV, HBV, influenza, RSV,  Plasmodium falciparum , and  C. difficle.    
     
     
         4 . The composition of  claim 3 , wherein the HPV antigen is E6 and E7 domains of subtypes selected from the group consisting of: HPV6, HPV11, HPV18, HPV31, HPV33, HPV52, and HPV58, and a combination thereof. 
     
     
         5 . The composition of  claim 3 , wherein the HIV antigen is selected from the group consisting of: Env A, Env B, Env C, Env D, B Nef-Rev, and Gag, and a combination thereof. 
     
     
         6 . The composition of  claim 3 , wherein the influenza antigen is selected from the group consisting of: H1 HA, H2 HA, H3 HA, H5 HA, BHA antigen, and any combination thereof. 
     
     
         7 . The composition of  claim 3 , wherein the  Plasmodium falciparum  antigen includes a circumsporozoite (CS) antigen. 
     
     
         8 . The composition of  claim 3 , wherein the  C. difficle  antigen is selected from the group consisting of: Toxin A, and Toxin B, and a combination thereof. 
     
     
         9 . The composition of  claim 3 , wherein the HCV antigen is selected from the group consisting of: E1, E2, NS3, NS4a, NS4b, NS5a, and NS5b, and a combination thereof. 
     
     
         10 . The composition of  claim 3 , wherein the HBV antigen is selected from the group consisting of: surface antigen type A, surface antigen type B, surface antigen type C, surface antigen type D, surface antigen type E, surface antigen type F, surface antigen type G, surface antigen type H, and core antigen, and a combination thereof. 
     
     
         11 . The composition of  claim 3 , wherein the RSV antigen is selected from the group consisting of: F, G, NS1, NS2, N, M, M2-1, M2-2, P, SH, and L protein, and a combination thereof. 
     
     
         12 . The composition of  claim 3 , wherein the synthetic antigen is hTERT. 
     
     
         13 . The composition of  claim 3 , wherein the prostate antigen is selected from the group consisting of: PSA, PSMA, STEAP, PSCA, and PAP, and a combination thereof. 
     
     
         14 . The composition of  claim 3 , wherein the synthetic antigen is selected from the group consisting of WT1 antigen, tyrosinase, NYES01, and PRAME. 
     
     
         15 .- 17 . (canceled) 
     
     
         18 . The composition of  claim 3 , wherein the synthetic antigen is a herpes antigen, wherein the herpes is HCMV, HSV1, HSV2, VZV, or CMV, and the herpes antigen is selected from the group consisting of gB, gM, gN, gH, gL, gO, gE, gI, gK, gC, gD, UL128, UL130, UL131A, and UL83. 
     
     
         19 . The composition of  claim 1 , wherein the PD1 antibody and PDL1 antibody is selected from the group consisting of: nivolumab, pembrolizumab, pidilizumab, BMS-936559, MPDL3280A, MDX1105-01, MEDI4736, and MK-3475. 
     
     
         20 . The composition of  claim 1 , further comprising a pharmaceutically acceptable excipient. 
     
     
         21 . A method for increasing an immune response in a subject in need thereof, the method comprising administering the composition of  claim 1  to the subject. 
     
     
         22 . The method of  claim 21 , wherein administering the composition comprises an electroporating step.